News from NORD

Letter to Congress: NORD and Others Oppose “Right to Try”

Publish date: February 12, 2018

 

NORD and 40 other patient organizations and professional societies have sent a letter to the leadership of the US House of Representatives explaining why they oppose “Right to Try” legislation currently being considered by Congress. Signers of the letter include the American Society of Clinical Oncology, Leukemia & Lymphoma Society, American Lung Association, and National Health Council. The organizations say they support patients being given access to unapproved therapies but believe the bills under consideration will not increase patient access.

Recommended Reading

Disfiguring Ulcerative Neutrophilic Dermatosis Secondary to Doxycycline and Isotretinoin in an Adolescent Boy With Acne Conglobata
MDedge Dermatology
Cases link vitiligoid lichen sclerosus and darker skin
MDedge Dermatology
Differentiating Trigeminal Motor Neuropathy and Progressive Hemifacial Atrophy
MDedge Dermatology
Yellow-Orange Hairless Plaque on the Scalp
MDedge Dermatology
Tumor Necrosis Factor α Inhibitors in the Treatment of Toxic Epidermal Necrolysis
MDedge Dermatology
Primary Cutaneous Follicle Center Lymphoma Mimicking Folliculitis
MDedge Dermatology
Melkersson-Rosenthal Syndrome Successfully Treated With Adalimumab
MDedge Dermatology
Panniculitis, Pancreatitis, and Polyarthritis: A Rare Clinical Syndrome
MDedge Dermatology
NORD to Moderate Panel at NIH Rare Disease Day Event
MDedge Dermatology
Rare Disease Day Events Planned for Campuses, Hospitals, and State Legislatures
MDedge Dermatology